This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.


29Nov 2019

Back to Seminars overview

International seminar by Michal Besser

Michal Besser
Head of the Clinical Laboratory at the Ella Institute, Ramat Gan, Israel
Adoptive cell therapy with on-site produced TIL or CD19 CAR T cells - Updated results of 300 enrolled patients

Friday, November 29, 2019, 11.00 hrs
Piet Borst Auditorium    

Host: Joost van den Berg and Pia Kvistborg

Michal Besser
Michal Besser, PhD is the head of laboratory at The Ella Lemelbaum Institute for Immuno-Oncology and the director of the Wohl GMP facility at the Sheba Medical Center in Israel. Dr. Besser is an assistant professor at the Department of Clinical Immunology and Microbiology at Tel Aviv University. She     completed her undergraduate studies and PhD at the University of Munich,Germany and her postdoctoral research at the Weizmann Institute of Science, Israel. The Besser lab is specialized in the clinical production of CAR T cells and Tumor Infiltrating Lymphocytes (TIL) for therapy of cancer     patients. Adoptive cell therapy serves as a platform for a wide range of  research projects, which mainly seek the understanding and improvement of cellular therapies and immunotherapy.


Share this page